Comparative Bioavailability study of a Novel Multi-day Patch Formulation of Rivastigmine (twice weekly) with Exelon ® Transdermal Patch (daily). A randomized clinical trial

CONCLUSION: Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon® once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.TRIAL REGISTRATION NUMBER: Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18.PMID:36017827 | DOI:10.2174/1567205019666220823105059

Source: Current Alzheimer Research - August 26, 2022 Category: Neurology Authors: Bjoern Schurad Cornelius Koch Barbara Schug Adelaida Morte Anna Vaqu é Rafael De la Torre Marc Iniesta Source Type: research